Medikamentöse Behandlung der Immunhyperthyreose (Typ Morbus Basedow)

[1]  B Gerbert,et al.  [Thyroid hormone and the cardiovascular system]. , 2005, Deutsche medizinische Wochenschrift.

[2]  I. Klein,et al.  Thyroid hormone and the cardiovascular system. , 2001, Minerva endocrinologica.

[3]  U. Roggenbuck,et al.  Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. , 2002, Thyroid.

[4]  B. Nygaard,et al.  Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. , 2002, European journal of endocrinology.

[5]  D. Glinoer,et al.  Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. , 2001, European journal of endocrinology.

[6]  R. Hampel,et al.  Jodidurie bei Schulkindern in Deutschland 1999 im Normbereich , 2001, Medizinische Klinik.

[7]  W. Waldhäusl,et al.  Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. , 2000, European journal of endocrinology.

[8]  C. Massart,et al.  Antithyroid drugs and Graves' disease — prospective randomized assessment of long‐term treatment , 1999, Clinical endocrinology.

[9]  K. Usadel,et al.  Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. , 1999, The Journal of clinical endocrinology and metabolism.

[10]  J. Bringer,et al.  TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates , 1998, Clinical endocrinology.

[11]  R. Rittmaster,et al.  Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. , 1998, The Journal of clinical endocrinology and metabolism.

[12]  A. Pinchera,et al.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. , 1997, Thyroid : official journal of the American Thyroid Association.

[13]  R. Ziegler,et al.  Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume. , 1997, European journal of endocrinology.

[14]  P. Rae,et al.  Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. , 1996, The New England journal of medicine.

[15]  J. Hershman.  Does thyroxine therapy prevent recurrence of Graves' hyperthyroidism? , 1995, The Journal of clinical endocrinology and metabolism.

[16]  S. Nagataki,et al.  Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. , 1995, The Journal of clinical endocrinology and metabolism.

[17]  V. Chatterjee,et al.  Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. , 1994, The Quarterly journal of medicine.

[18]  P. Carayon,et al.  Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. , 1994, The Journal of clinical endocrinology and metabolism.

[19]  W. Alexander,et al.  A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. , 1993, The Journal of clinical endocrinology and metabolism.

[20]  M. Prummel,et al.  Smoking and Risk of Gravesʼ Disease , 1993 .

[21]  M. Prummel,et al.  Smoking and risk of Graves' disease. , 1993, JAMA.

[22]  D. Glinoer,et al.  Reassessment of antithyroid drug therapy of Graves' disease. , 1993, Annual review of medicine.

[23]  G. Medeiros-Neto.  Administration of thyroxine in treated Graves' disease. , 1991, The New England journal of medicine.

[24]  S. Nagataki,et al.  Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. , 1991, Thyroid : official journal of the American Thyroid Association.

[25]  R. Fauchet,et al.  Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. , 1990, The Journal of clinical endocrinology and metabolism.

[26]  G. Kahaly,et al.  New therapeutic approaches in thyroidal autoimmune diseases. , 1990, Klinische Wochenschrift.

[27]  N. Farid,et al.  Association between Graves' ophthalmopathy and smoking. , 1990, Lancet.

[28]  G. Benker,et al.  [Side effects of antithyroid therapy of hyperthyroidism. A study of 1256 continuously treated patients]. , 2008, Deutsche Medizinische Wochenschrift.

[29]  R. Holle,et al.  Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. , 1989, Acta endocrinologica.

[30]  P. Laurberg,et al.  Goitre size and outcome of medical treatment of Graves' disease. , 1986, Acta endocrinologica.

[31]  W. Marsden.  NON-PROFESSIONAL CIRCULAR. , 1834 .